Aprea Therapeutics disclosure: reporting persons report beneficial ownership of 1,186,294 shares (9.9% of the class). The filing states the total includes 170,753 common shares issuable upon exercise of warrants and excludes 10,155,621 warrants that are not currently exercisable due to beneficial ownership limitations. The filing attributes sole voting power for 1,015,541 shares and sole dispositive power for 1,186,294 shares to the reporting persons, which are AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman.
Positive
None.
Negative
None.
Insights
Joint holders disclose a near-10% beneficial stake with warrants included and limited exercise capacity.
The filing lists 1,186,294 shares beneficially owned representing 9.9% of the class and shows 170,753 shares issuable upon warrant exercise. It also notes 10,155,621 warrants are presently non-exercisable because of beneficial ownership limits.
This is a standard Rule 13d-1 disclosure clarifying ownership, voting power, and exercise limitations; subsequent filings will show any changes in exercisability or percent ownership.
Disclosure clarifies control and dispositive authority among affiliated entities and an individual.
The report attributes sole voting power for 1,015,541 shares to the reporting persons and identifies the principal business address. The signatures show Orin Hirschman as a reporting person and managing member.
Filing conforms to beneficial ownership reporting standards; changes in warrant exercisability would materially alter reported figures.
Key Figures
Beneficially owned:1,186,294 sharesPercent of class:9.9%Sole voting power:1,015,541 shares+2 more
5 metrics
Beneficially owned1,186,294 sharesAmount beneficially owned reported in Item 4
Percent of class9.9%Percent of class reported in Item 4
Sole voting power1,015,541 sharesSole power to vote reported in Item 4(c)(i)
Shares issuable on warrants (included)170,753 sharesIncluded in beneficial ownership as exercisable warrants
Warrants excluded from exercisability10,155,621 warrantsExcluded due to beneficial ownership limitations
Key Terms
beneficial ownership limitations, sole dispositive power, warrants issuable upon exercise
3 terms
beneficial ownership limitationsregulatory
"excludes 10,155,621 warrants not currently exercisable due to beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
sole dispositive powerfinancial
"Sole Dispositive Power 1,186,294.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
warrants issuable upon exercisefinancial
"Includes 170,753 common shares issuable upon exercise of warrants"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Aprea Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
03836J102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
03836J102
1
Names of Reporting Persons
Orin Hirschman
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,015,541.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,186,294.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,186,294.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
03836J102
1
Names of Reporting Persons
AIGH Capital Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,015,541.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,186,294.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,186,294.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aprea Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
535 Boylston Street, Boston, MA, 02116
Item 2.
(a)
Name of person filing:
This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"):
(i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., and WVP Emerging Manger Onshore Fund, LLC - AIGH Series.
(ii) AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC";), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;
(iii) Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly.
AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
(b)
Address or principal business office or, if none, residence:
The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr.Hirschman is: 6006 Berkeley Avenue, Baltimore MD 21209
(c)
Citizenship:
See Item 2(a) above and Item 4 of each cover page.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
03836J102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1,186,294
Includes 170,753 common shares issuable upon exercise of warrants and excludes 10,155,621 warrants not currently exercisable due to beneficial ownership limitations on exercise
(b)
Percent of class:
9.9 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1,015,541
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
1,186,294
Includes 170,753 common shares issuable upon exercise of warrants and excludes 10,155,621 warrants not currently exercisable due to beneficial ownership limitations on exercise
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does AIGH report in Aprea Therapeutics (APRE)?
The filing reports 1,186,294 shares beneficially owned, representing 9.9% of the class. This total includes 170,753 shares issuable upon exercise of certain warrants and lists voting and dispositive powers held by the reporting persons.
How many warrants related to APRE are excluded from exercisability?
The filing excludes 10,155,621 warrants from current exercisability due to beneficial ownership limitations. The report separately counts 170,753 common shares that are exercisable and included in the beneficial ownership total.
Who are the reporting persons named in the APRE Schedule 13G/A?
The reporting persons are AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman. The filing states their principal business address as 6006 Berkeley Avenue, Baltimore, MD.
What voting and dispositive powers are reported for APRE holdings?
The disclosure shows sole voting power for 1,015,541 shares and sole dispositive power for 1,186,294 shares attributed to the reporting persons. No shared voting or dispositive powers are reported.
Does the APRE filing indicate who signs the report?
Yes. The filing is signed by Orin Hirschman, including a signature block identifying him as Managing Member. The signature date is shown as April 27, 2026.
